Cancer; a biological approach. I. The processes of control
about
Can tissue-based immune markers be used for studying the natural history of cancer?CAM and NK CellsRevisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapyThe Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer ProgressionNovel technologies and emerging biomarkers for personalized cancer immunotherapyA Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All CancersBeneficial autoimmunity at body surfaces - immune surveillance and rapid type 2 immunity regulate tissue homeostasis and cancerTumor-primed NK cells: waiting for the green lightControl of the immune response by pro-angiogenic factorsImmunotherapy in gastric cancerCheckpoint modulation--A new way to direct the immune system against renal cell carcinomaDevelopment and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progressionThe concept of immune surveillance against tumors. The first theoriesPOLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial CancerAnti-tumor immunity: myeloid leukocytes control the immune landscapeImpaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma ModelIL-13 from intraepithelial lymphocytes regulates tissue homeostasis and protects against carcinogenesis in the skinRational combinations of immunotherapeutics that target discrete pathways.Cancer Immunoprevention and Public Health.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Immunotherapy for solid tumors--a review for surgeons.Revisiting the hallmarks of cancer.Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasisVaccine prevention of cancer: can endogenous antigens be targeted?Bridging innate and adaptive antitumor immunity targeting glycans.Methodological issues for determining intervals of subsequent cancer screeningIatrogenic alterations of immunologic surveillance in man and their influence on malignancy.Cancer immunotherapy in clinical practice -- the past, present, and future.New roads open up for implementing immunotherapy in mesothelioma.How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?Malignant tumors arising de novo in immunosuppressed organ transplant recipients.Translating tumor antigens into cancer vaccinesCell-Mediated Immune Responses of Preleukemic AKR Mice.Combinations of immunotherapy and radiation in cancer therapy.Review: cancer-induced autoimmunity in the rheumatic diseases.Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.Principles of tumor immunosurveillance and implications for immunotherapy.Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology.Cancer vaccines at an inflexion point: what next?
P2860
Q24605537-98C68139-22A4-436C-8EF2-25126FB91F49Q24799074-EDAEB953-8ADE-4488-9BA6-21CB7717481AQ24805285-BFFED435-5A87-4D42-ABD0-E84936E0DC41Q26750877-504D1634-603A-494C-B4BC-12F7FDBD6D89Q26770780-DE66E662-C473-42BD-8E28-BC1B9BD14FC7Q26777111-0F6D20C9-8443-42C0-903B-17561D649574Q26865509-A5021E12-00DF-4B76-AABA-5AAB55542BD8Q26999306-A4E219F6-F24F-469E-B812-FA3CAE99C3C3Q27004733-AEB529ED-172A-4260-AAC5-78E0CC8F7C15Q27010472-F02183DA-CA4C-4BCE-BD3E-B6BCC36DB092Q27025873-5E2D07E8-B043-420A-A0F6-998038BED859Q27325140-79CBA6DF-5D90-4BAF-8DDF-878A5696D2BCQ28073937-09AF4283-7008-436D-A005-A7092F36A97BQ28260529-7C5C241F-5B94-447B-A7D1-CE1718C77D24Q28390573-ECF8364D-9C35-4EB7-B637-4735BD342FB3Q28607232-2F7DD815-87DB-4A90-B18D-531D1DEFEA75Q28831392-B7919422-4160-42D6-86B0-D0F8F7916DACQ33606144-085B2783-0D43-4F96-9035-C136F5C79962Q33646584-50B51A1F-3104-46FB-A14B-AE024C58BB2FQ33660069-257938FB-A3C6-463F-B03A-DA77B20F8F4CQ33709232-4E8D386B-C7C4-4180-8F57-A0F96DC7297BQ33732986-20160A42-3A62-4AF8-BDB4-9343972B6D91Q33762632-77C343CD-AA56-4643-A33C-B956E23B981CQ33783609-F8B9B59C-8726-4C93-8BDB-C13CD2744F5CQ33960021-BA2CBC21-8B3B-4F66-A09F-C56ADFF9289AQ34125697-FC702F8E-8C9D-4668-AC8C-399573D397A3Q34305014-8ED842CD-EBAE-412E-A24F-1EEE9C426640Q34309399-9183ED4E-682E-4AB5-8EBD-01712290CB43Q34331993-A2649901-9FB8-4921-82C1-EBCAB9021C4EQ34418112-2F32E393-BF62-467E-A6A0-A0B5655AEA59Q34425671-97020544-9DBF-48D7-BF2C-BD33E7D83764Q34484042-181C48EC-C5DD-435A-968E-4814A68EF286Q34503803-D0A42E78-CEDA-43F9-B08B-D72C1EF6114DQ34582640-2DD70572-9078-4D06-8759-DD7931CBF7D6Q34666066-6FBAAC58-6DFF-4A6C-993F-B61B9AB84E57Q35022833-C10EA7B7-33E0-4209-8BD8-11A3FEC5D8E2Q35033249-C29FB436-285C-40E1-B6CA-FF90383ABE73Q35043113-46299420-1148-4523-8EAF-490478A03FC8Q35140467-375A7E31-752B-497D-A25B-C07D28BB1193Q35218626-B2C3FB95-409E-4A26-ABD4-62A1E0E2C537
P2860
Cancer; a biological approach. I. The processes of control
description
1957 nî lūn-bûn
@nan
1957 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1957 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1957年の論文
@ja
1957年論文
@yue
1957年論文
@zh-hant
1957年論文
@zh-hk
1957年論文
@zh-mo
1957年論文
@zh-tw
1957年论文
@wuu
name
Cancer; a biological approach. I. The processes of control
@ast
Cancer; a biological approach. I. The processes of control
@en
Cancer; a biological approach. I. The processes of control
@nl
type
label
Cancer; a biological approach. I. The processes of control
@ast
Cancer; a biological approach. I. The processes of control
@en
Cancer; a biological approach. I. The processes of control
@nl
prefLabel
Cancer; a biological approach. I. The processes of control
@ast
Cancer; a biological approach. I. The processes of control
@en
Cancer; a biological approach. I. The processes of control
@nl
P3181
P356
P1433
P1476
Cancer; a biological approach. I. The processes of control
@en
P2093
P304
P3181
P356
10.1136/BMJ.1.5022.779
P407
P577
1957-04-06T00:00:00Z